Sun et al. demonstrated that a monoclonal antibody (Y4) against KCNK9 extracellular-domain effectively inhibits growth of human lung cancer xenografts and BC metastasis in mice, and suggest that antibody-based KCNK9 targeting is a promising therapeutic strategy in KCNK9 overexpressing malignancies [32]. This evidence concerns the gene KCNK9 and breast cancer.